ABSTRACT

Background: Brain abscess by definition is a crucial pus collection inside the brain, resulted from the infection by a variety of bacteria, fungi, and parasite. It can be single or multiple. The size, position, and number of lesions, as well as the organism’s pathogenicity, host reactions, and the severity of cerebral edema, all influence the presentation.

Objective: To assess how well a brain abscess was managed and to evaluate the patients with favorable and unfavorable Glasgow outcome scale (GOS).

Patients and methods: From January 2014 to January 2021, the study was achieved and conducted in the Neurosurgical Department of Ibn-Sina Teaching Hospital on Mosul's left coast. The neurosurgery unit managed a case series investigation of 70 patients who had a brain abscess. Age, sex, duration of illness, initial neurosurgical status, and abscess features are among the clinical data. A comparison was performed between patient with Favorable Glasgow outcome scale (GOS), moderate disability or those with good recovery and those with Unfavorable GOS, death or persist vegetate status outcome at discharge.

Results: The study involved 48 male and 22 female patients (male / female ratios 2.2:1). The series consist of 52 patients who experienced favorable outcome and 18 resulted from an unfavorable outcome. The mean of age for those patients was 20 years. The difference between males and females regarding favorable and unfavorable outcomes is insignificant. P-value was significant in cyanotic congenital heart diseases as cause of brain abscess were particularly prevalent among the children (adult VS children = 1:9). The most common site for single abscesses was the frontal lobe (25 patients), and majority of patients treated with burr hole drainage, which had the best results.

Conclusion: Although there were technological improvement of imaging and antibiotics treatment, the mortality of brain abscesses is still relatively high, especially among those with decreased level of consciousness on admission.

Keywords: Brain Abscess, Outcomes, Mortality.
INTRODUCTION

Brain abscess by definition is a crucial pus collection inside the brain, resulted from the infection by a variety of bacteria, fungi, and parasite. It can be single or multiple 4.

Historically speaking, MacEwen in 1876 made his first definition and localizing classification of brain abscess 5. According to studies, brain abscesses account for roughly 8% of intracranial lumps in underdeveloped nations while in Western countries, it account for 1% to 2%, with four instances per million, it depends on geographic location and living standards within a given region. The incidence is higher in underdeveloped countries where the living conditions remain poor 6.

Contiguous infection of the mastoid, middle ear, and paranasal sinuses are the most frequent causes of underlying infection in most clinical series 4.5. Hematogenous dissemination (Metastatic abscess) , Cyanotic congenital cardiac disease, Immunocompromised patient and previous craniotomy are other source of brain abscess.

The size, position, and number of lesions, as well as the organism's pathogenicity, host reactions, and the severity of cerebral edema, all influence the presentation 6. There is no single symptom that is pathognomonic for a brain abscess 7. The most widespread symptoms of brain tissue destruction and edema are broad indicators of high intracranial pressure and local neurological impairment 8.

Brain abscess symptoms are difficult to distinguish from those of a tumor or other space-occupying lesion. The clinical features of an abscess, alternatively, tend to progress more quickly than those of a tumor 9,10.

The symptoms become obvious within the early 2 weeks in 75% of patients 11. The headache is prominent in 70%-97% 12; it is frequently constant progressive and refractory to therapy. Nausea and vomiting occur in 25%-50%, and more than 50% of patients have documented fever at the time of diagnosis usually of low grade. Alteration of consciousness is present in up to two thirds of patients 11,12. This ranges from mild confusion and drowsiness to obtundation and coma. Hemiparesis, Ataxia, and nystagmus are frequent symptoms of cerebellar abscesses 13.

The laboratory Findings include:

1. Blood analysis: this done by the peripheral leukocyte count which is frequently normal or only mildly elevated (less than 15,000/m) in up to 70% of patients. Moreover, the erythrocyte sedimentation rate (ESR) is elevated in up to 80% of patients in whom it is measured. The ESR averaged between 5 to 110 mm/h 14,15.

2. Cerebrospinal fluid (CSF) analysis: CSF analysis yields vague results. Unless there is concurrent meningitis 16,17.

3. Image Study: A computed tomography (CT) scan with contrast administration is a quick way to determine the size, number, and location of abscesses, classification, and staging in addition to the follow-up care 18,19. Magnetic resonance imaging (MRI) provides imaging detail and resolution superior to CT scanning. It is more sensitive and accurate than CT in detecting early cerebritis.
Antibiotic effectiveness, concentration, duration, and specific organism response are all effective treatments. Surgical drainage or excision in combination with prolonged antibiotics (typically 4-8 weeks) is the preference option of treatment once an abscess has formed and is larger than 2.5 cm. Corticosteroids are administered to manage cerebral edema and are contentious. Needle aspiration through the burr hole is the preferable method, which can be accomplished using a stereotactic operation aided by ultrasonography or CT scanning. Patients treated solely with aspiration show excellent outcomes.

Craniotomy is generally performed in patients with multi-loculated abscesses, cerebellar abscesses, traumatic abscesses, fungal abscesses.

MATERIALS AND METHODS
A case series study of 70 patients presenting with brain abscess was managed by neurosurgical unit in Ibn-Sina Hospital for the period from January 2014 to January 2021. All patients' data and records were obtained from the patient examination and follow up.

Clinical data include: Age, sex, medical history, duration of symptom, and the initial neurosurgical status. Potential prognostic factors were linked predisposing variables, laboratory data, and abscess features. CT-scan revealed the location of the abscess.

Antibiotic drug therapy given to those in early cerebritis stage and to those with multi-loculated abscesses, cerebellar abscesses, traumatic abscesses, fungal abscesses. Antibiotic drug therapy given to those in early cerebritis stage and to those with multi-loculated abscesses, cerebellar abscesses, traumatic abscesses, fungal abscesses. Corticosteroids are administered to manage cerebral edema and are contentious. Needle aspiration through the burr hole is the preferable method, which can be accomplished using a stereotactic operation aided by ultrasonography or CT scanning. Patients treated solely with aspiration show excellent outcomes.

Craniotomy is generally performed in patients with multi-loculated abscesses, cerebellar abscesses, traumatic abscesses, fungal abscesses.

An assessment was done between patients with
1. Favorable (GOS) Glasgow outcome scale: good recovery (5) or moderate disability (4).
2. Unfavorable (GOS): severe disability (3), persist vegetate status (2), death (1) at discharge.

Level of consciousness was divided into (Glasgow coma scale) GCS >12 & ≤ 12 to make easy follow up and prognosis.

Univariate Chi square test analysis or Fisher's exact test was calculated to identify prognostic factors. The data were considered significant when the tailed p-value was ≤0.05.

We calculated the end-outcome incidence for every data set separately. After the admission period (6 weeks –6 months), the follow-up for 6 months begins. Only a few patients have long-standing follow-up information.

RESULTS
I- Age and Sex
The mean age of those patients is 19.7±14.0 years ranging from (3 month-60 year). There were 48 male and 22 female patients (male / female ratio 2.2:1). There is 21 children among the study sample Table 1.

Table (1) Demonstrate initial presentation of the patients according to (age and sex)

| Age and sex | Favorable | Unfavorable | Total | P-value |
|-------------|-----------|-------------|-------|---------|
|             | No. (%)   | No. (%)     | No. (%) |         |
| Male        | 37 (71.0) | 11 (61.0)   | 48 (68.5) | NS      |
| Female      | 15 (29.0) | 7 (39.0)    | 22 (31.5) |         |
| Total       | 52        | 18          | 70     |         |
| Age/years mean± SD | 19.2±14.3 | 18.4±14.3 | 19.7±14.0 | 0.838 ** |

*Chi square test  ** t-test  NS= not significant

II- Sign and Symptom
Table (2) demonstrates the initial presentation of the patients according to duration with the signs and symptoms and revealed that, the mean duration of symptoms before being diagnosed by image studies was 14 ± 20 days. On admission, most patients had neurological manifestations such as focal neurological deficits and signs associated with increased intracranial pressure (ICP) (headache, nausea, vomiting, and papilledema). Fever was common and occurred in 40 patients 57.0%, 15(21.15%) of them had temperature of 38.5°C or higher. However, the classic triad of brain abscesses: fever, headache and focal neurological deficits are present in 24 patients (34.0%). The level of consciousness of the patients also shown in Table (2).
Table (2): Duration with Sign and Symptom of the patients.

|                | Favorable | Unfavorable | Total | P-value |
|----------------|-----------|-------------|-------|---------|
| Duration of symptom/day mean±SD | 14 ±20 | 14.4 ± 20 | 12.0 ±19.0 | NS |
| Sign Suggesting IICP | 31 (59.5%) | 10 (55.5%) | 41 (58.5%) | NS |
| Focal neurological deficit | 28 (54.0%) | 8 (44.5%) | 36 (51.5%) | NS |
| Seizure | 8 (15.0%) | 2 (11.0%) | 10 (14.5%) | NS |
| Fever | 32 (61.5%) | 8 (44.5%) | 40 (57.0%) | NS |
| GCS>12 | 45 (86.5%) | 9 (50.0%) | 54 (77.0%) | 0.001* |
| GCS≤ 12 | 7 (13.5%) | 9 (50.0%) | 16 (23.0%) | 0.001* |

IICP= increase intracranial pressure NS= not significant *Fisher's exact test

Table (3) demonstrates the initial presentation of the patients according to the source of infection and illustrates that, hematogenous origin, contiguous origin, being diabetic, and immune compromised are statistically insignificant.

Table (3): The initial presentation of the patients according to the source of infection.

|                | Favorable | Unfavorable | Total | P-value |
|----------------|-----------|-------------|-------|---------|
| Hematogenous origin | 18 (39.1%) | 7 (29.1%) | 25 (35.7%) | NS |
| Contiguous origin | 13 (28.2%) | 5 (7.1%) | 18 (25.7%) | NS |
| Diabetes mellitus | 7 (10%) | 4 (5.7%) | 11 (15.7%) | NS |
| Immune compromised | 8 (17.4%) | 8 (11.4%) | 16 (22.8%) | NS |

*Chi square test NS= not significant

Table (4) demonstrates the hematogenous metastasis among the patients and shows that, the hematogenous metastasis associated with cyanotic heart diseases in 14.0% (1.5% in adults and 12.5% in children) with a very highly significant difference in between, 20% with lung infection and 1.5% with liver abscess.

Table (4): Hematogenous metastasis.

| Hematogenous metastasis | No | %   | p-value |
|-------------------------|----|-----|---------|
| Cyanotic heart diseases  |    |     |         |
| Adult                   | 1  | 1.5%|         |
| Children                | 9  | 12.5%| 0.001* |
| Total                   | 10 | 14.0%|         |
| Lung infection          | 14 | 20% |         |
| Liver abscess           | 1  | 1.5% |         |
| Total                   | 25 | 35.7%|         |

* Fisher’s exact test.

Table (5) illustrates the counts and the percentages of contiguous infection and demonstrates that, the contiguous infection presents in 18 patients constituting 25.7%. Otitis media found in 8 patients representing 11.4%, chronic mastoditis found in 6 patients representing 8.6% and only 4 patients have penetrating head injury and represents 5.7%.

Table (5): Contiguous infection.

| Contiguous infection | No | %   |
|----------------------|----|-----|
| Chronic otitis media | 8  | 11.4%|
| Chronic mastoditis   | 6  | 8.6%|
| Penetrating head injury | 4 | 5.7%|
| Total                | 18 | 25.7%|

Table (6) demonstrates the distribution of immune compromised patients and shows that, steroid drugs given to nephrotic syndrome and chronic asthma found in 10% of the patients, while hematological disorders, like chronic myeloid leukemia and aplastic anemia found in 12.8%.

Table (6): Immune compromised patients.

| Immune compromised                                     | No | %   |
|--------------------------------------------------------|----|-----|
| Steroid drug to nephrotic syndrome & chronic asthma    | 7  | 10% |
| Hematological disorder, chronic myeloid leukemia & aplastic anemia. | 9  | 12.8%|
| Total                                                  | 16 | 22.8%|

Table (7) demonstrates the characteristics of brain abscess according to pathology and reveals that, the differences between favorable and unfavorable were statistically insignificant regarding specimen, Gram (+ve) cocci, Gram (-ve) cocci, anaerobes, and fungus.
Table (7): Characteristics of Brain abscess according to Pathology.

| Abscess characteristic | Favorable | Unfavorable | Total | P-value |
|------------------------|-----------|-------------|-------|---------|
| Sterile or no specimen | 20 (38.5%) | 9 (50.0%) | 29 (41.5%) | NS |
| Gram (+ve) cocci       | 16 (30.5%) | 2 (11.0%) | 18 (25.5%) | NS |
| Gram (-ve) Cocci       | 7 (13.5%) | 3 (16.5%) | 10 (14.0%) | NS |
| Anaerobes              | 9 (7.5%) | 3 (16.5%) | 12 (17.0%) | NS |
| Fungus                 | 0 (0.0%) | 1 (5.5%) | 1 (1.5%) | NS |
| Total                  | 52 | 18 | 70 | NS= not significant |

Table (8) shows the distribution of brain abscess characteristics according to the abscess location and depicts that, frontal site represents 34.5% of the favorable and 39.0% in unfavorable, the temporal accounts 17.5% in the favorable and 16.5% in unfavorable. The parietal constitutes 17.5% and 5.5%; the occipital 4.0% and 11.0%; posterior fossa 7.5% and 5.5%; the multiple abscesses 19.0% and 22.5% in favorable and unfavorable respectively in the same manner. The differences show insignificant p-value for the comparison between favorable and unfavorable.

Table (8): Brain abscess characteristics of patients according to abscess location.

| Abscess characteristic | Favorable | Unfavorable | Total | P-value |
|------------------------|-----------|-------------|-------|---------|
| Frontal                | 18 (34.5%) | 7 (39.0%) | 25 (35.5%) | NS |
| Temporal               | 9 (17.5%) | 3 (16.5%) | 12 (17.0%) | NS |
| Parietal               | 9 (17.5%) | 1 (5.5%) | 10 (14.0%) | NS |
| Occipital              | 2 (4.0%) | 2 (11.0%) | 4 (5.5%) | NS |
| Posterior Fossa        | 4 (7.5%) | 1 (5.5%) | 5 (7.0%) | NS |
| Multiple abscesses     | 10 (19.0%) | 4 (22.5%) | 14 (20.0%) | NS |
| Total                  | 52 | 18 | 70 | NS= not significant |

Table (9) demonstrates the distribution of brain abscess characteristics according to treatment and reveals that, among the favorable, the medical treatment, burr hole, and excision represent 13.5%, 67.5%, and 19.0% respectively, which are insignificantly, differ from that of unfavorable arrange as16.5%, 72.5%, and 11.0% respectively.

Table (9): Brain abscess characteristics according to Treatment.

| Abscess characteristic | Favorable | Unfavorable | Total | P-value |
|------------------------|-----------|-------------|-------|---------|
| Medical treatment      | 7 (13.5%) | 3 (16.5%) | 10 (14.0%) | NS |
| Burr hole              | 35 (67.5%) | 13 (72.5%) | 48 (68.5%) | NS |
| Excision               | 10 (19.0%) | 2 (11.0%) | 12 (17.0%) | NS |
| Total                  | 52 | 18 | 70 | NS= not significant |

Table (10) shows the outcomes of the disease and demonstrates that, the full recovery occurs in 50.0% of the patients. The mild deficits represent 24.0%. Death occurs during the hospitalization of 17.0%, while severe disability accounts for only 9.0% of the patients.

Table (10): Outcomes of the disease.

| Outcome                  | Favorable outcome | Unfavorable outcome | Total No. (%) |
|--------------------------|-------------------|---------------------|---------------|
| Favorable outcome        |                   |                     |               |
| Full recovery            | 35 (50.0%)        |                     | 52 (74.0%)    |
| Mild deficits            | 17 (24.0%)        |                     |               |
| Unfavorable outcome      |                   |                     |               |
| Died during hospitalizati on | 12 (17.0%)    |                     | 18 (26.0%)    |
| Severe disability        | 6 (9.0%)          |                     |               |
| Total                    | 70 (100.0%)       | 70 (100.0%)         |               |
DISCUSSION

A male preponderance was noticed in this study with the fraction of 2.2 male: 1 female and this result was corresponding to the findings in other reported literatures. However, a difference was not seen in other studies.

The early manifestations frequently correlate with the location, size, evolution of the abscess, virulence of infecting pathogens, and underlying host situations. In the present study, the main symptoms are due to IICP (nausea, vomiting, and headache) in 41 (58.5%). Fever is also a common finding 40 (57.0%) as shown in table (2), which is similar to others studies.

The position and mass effect of the abscess determine focal neurological abnormalities; in our study, 36 (51.5%) in other investigations more than 60%.

Hematogenous spread is common in the present study, and was found in 25 (35.7%) which is more than contiguous spread 18 (25.7%). Other studies show that, the contiguous source is the most frequent. Diabetes mellitus is 11(15.7%) and immune compromised 16 (22.8%) were lower than other studies as illustrated in table (3).

Most Hematogenous source was with a shunt from right to left or cyanotic type of congenital cardiac disease as in other study. Also it’s more in children, giving p-value 0.001 which is very highly significant as in table (4).

In patients with a shunt from right to left, decreased arterial oxygen saturation combined with increased blood viscosity owing to increased hemoglobin levels may cause focal ischemia in the brain that could serve as excellent nidi for infection.

Furthermore, because a shunt from right to left can skip the filter effect of pulmonary circulation, it has been suggested that correcting the shunt sooner rather than later may minimize the risk of abscess development in these patients.

The most common contiguous source is chronic otitis media 8 patients (11.4%), then chronic mastoiditis 6 patients (8.6%), then penetrating head injury 4(5.7%) patients as demonstrated in table (5), this incidence was low in comparable to other literatures.

In immune compromised patients abscesses are frequently caused by opportunistic organism (e.g., atypical bacteria, fungi, and parasites), which are not pathogenic in humans. Although the frequency of sterile culture is elevated, as shown in table (7), careful culturing of abscess resources attained at the instance of surgery affords the best chance to make a microbiological diagnosis, despite the fact that the incidence of sterile culture is similar to findings of other studies.

However, an initial broad–spectrum antibiotic coverage for the most common organisms should be the first choice for all critically ill patients, even if the culture results are being awaited. Because the microorganisms that cause brain abscesses are often similar to that causing other septic foci, the initial antibiotic coverage could be based on the most likely ones at the hypothesized entry points. Complete excision is preferable to simple drainage in situations caused by these more resistant infections, such as fungus or Nocardia species.

Some studies have supported nonsurgical treatment for patients who are poor surgical candidates or have surgically inaccessible lesions since 1975. The chief drawback of this strategy is the risk of toxicity associated with long-term empirical antibiotic therapy. The surgical treatment should be attempted, except during the period of cerebritis, in order to reduce the mass effect and get abscess materials for identifying infecting bacteria and, therefore, enabling antibiotic selection. The following management policy has been recommended by Mamack et al, aggressive surgical drainage of abscesses larger than 2.5cm in diameter, followed by antibiotics that given intravenously for 6 to 8 weeks and biweekly imaging studies for monitoring evidence of abscess re–expansion or failure to resolve despite antibiotics. With the availability of enhanced imaging studies, stereotactic procedures, and more broad–spectrum antibiotics, the role of aspiration has enlarged because of its simplicity. Stereotactic aspiration joints with antibiotic treatment can still be used in difficult-to-access places such as brain stems or eloquent areas in patients at high risk for surgery or with the multiple brain abscesses.

In the current study, 48 patients (68.5%) had aspiration via the burr hole and had a favorable outcome (67.5%), which was comparable to medical and excision (13.5%) and (19.0%), respectively, which was shown in table (9). Despite the fact that abscess excision is thought to reduce the clinical course, there has been no further improvement in the result.

With the advent of imaging technology and broad–spectrum antibiotics, our findings show that timely recognition of the diagnosis and effective infection control are critical to a favorable result. It is critical to identify the germs that are causing the abscess in order to manage it more effectively. When the clinical state allows, surgical techniques for acquiring culture materials should always be performed, even if the abscess is tiny (2.5cm), deeply seated, and/or numerous. Although there were technological improvements of imaging and antibiotic management, the morality of brain abscesses is still relatively high.
In the current work, the mortality was noticed in 17.0% as appears in table (10), which is similar to other studies (range, 17%-37%). The most important factor that influences mortality is the neurological condition of the patient at the time of diagnosis. And this appear clearly in our study, patients with GCS more than 12 show high favorable outcome (68.5%), in comparison to those with low GCS less than 12 whose show low favorable outcome (13.5%), with significant p-value as in table (2).

Another finding is that death is mainly caused by systemic infection or terminal cancer rather than directly by the brain abscess itself, suggesting that, although the current therapeutic strategy for controlling these abscesses is highly effective, the decisive factor for patients’ survival still depends on the host capability to combat offending pathogens.

CONCLUSIONS
1. Signs of IICP and disturbed consciousness are the main sign of brain abscess.
2. Poor state of consciousness on admission related to poor outcome and carries high mortality rate.
3. Patient who need burr hole treatment as indicated shows high favorable outcome in comparison to medical treatment and excision.
4. Mortality rate is high in this study 17.0%.

RECOMMENDATIONS
1. Early diagnosis of abscess in the brain of patient with chronic otitis media or congenital heart disease before a decline in level of consciousness.
2. Meticulous technique for bacteriological study for identification of offending pathogens.

Acknowledgment
The authors would like to thank in advance, the people in charge of the neurosurgical unit in Ibn-Sina Hospital for their cooperation in carrying out this study. Also special thanks to the ARC statistical center in Mosul for their statistical advice and assistance.

REFERENCES
1. Muzumdar D, Jhawar S, Goel A. Brain abscess: an overview. Int J Surg. 2011; 9(2):136-144.
2. Hernando Alvis Miranda, Sandra Milena Castellar-Leones, Mohammed Awad Elzain, Luis Rafael Moscote-Salazar. Brain abscess: Current management. J Neurosci Rural Pract. 2013 Aug; 4(Suppl 1): S67-S81. doi: 10.4103/0976-3147.116472.
3. Gorji GRS, Rassouli M, Staji H. Prevalence of cerebral toxoplasmosis among slaughtered sheep in Semnan, Iran. Ann Parasitol. 2018; 64(1): 37-42.
4. Mathisen GE, Johnson JP. Brain abscess. Clin Infect Dis. 1997; 25: 763–779.
5. Christine E. Hibberd TDN. Brain Abscess Secondary to a Dental Infection in an 11-Year-Old Child: Case Report. J Can Dent Assoc. 2012; 78: 49.
6. Brouwer MC1, van de Beek D. Epidemiology, diagnosis, and treatment of brain abscesses. CurrOpin Infect Dis. 2017. 30:129-134.
7. Helweg-Larsen J, Astradsson A, Richhall H, Erdal J, Laursen A, Brennum J. Pyogenic brain abscess, a 15 year survey. BMC Infect Dis. 2012. 12:332.
8. Brouwer MC, Coutinho JM, van de Beek D. Clinical characteristics and outcome of brain abscess: systematic review and meta-analysis. Neurology. 2014 Mar 4; 82 (9):806-813.
9. Lange N, Berndt M, Jörger AK, Wagner A, Wantia N, Lummel N, Ryang YM, Meyer B, Gempt J. Clinical characteristics and course of primary brain abscess. Acta Neurochir (Wien). 2018 Oct; 160(10): 2055-2062.
10. Udayakumaran S, Onyia CU, Kumar RK. Forgotten? Not Yet. Cardiogenic Brain Abscess in Children: A Case Series-Based Review. World Neurosurg. 2017 Nov; 107: 124-129.
11. Chen M, Low DCY, Low SYY. Muzumdar D, Seow WT. Management of brain abscesses: where are we now? Childs Nerv Syst. 2018 oct; 34(10): 1871-1880.
12. Widdrington JD, Bond H, Schwab U, Price DA, Schmid ML, McCarron B, Chadwick DR, Narayanan M, Williams J, Ong E. Pyogenic brain abscess and subdural empyema: presentation, management, and factors predicting outcome. Infection. 2018 Dec; 46(6): 785-792.
13. Cho SH, Park MK, Lee JD, Hwang SC. Otogenic brain abscess presenting with gait ataxia. *Korean J Audiol*. 2012; 16(1): 31-34. doi:10.7874/kja .2012.16.1.31

14. Miniar T, Amel BA, Khail S, Ben Helal BHK , Gueddiche GMN , Tilouce TS et al. Pyogenic brain abscess in children: a Tunisian multi-center experience. *Afr Health Sci*. 2018; 18(3): 560-568. doi:10.4314/ahs.v18i3.13

15. Patel K, Clifford DB. Bacterial brain abscess. *Neurohospitalist*. 2014; 4(4): 196-204. doi:10.1177/1941874414540684

16. Oyama H, Kito A, Maki H, Hatторi K, Noda T, Wada K. Inflammatory index and treatment of brain abscess. *Nagoya J Med Sci*. 2012; 74(3-4): 313-324.

17. Hirschberg H, Bosnes V. C-reactive protein levels in the differential diagnosis of brain abscesses. *J Neurosurg*. 1987; 67: 358–360.

18. Alvis Miranda H, Castellar-Leones SM, Elzain MA, Moscote-Salazar LR. Brain abscess: Current management. *J Neurosurg: Rural Pract*. 2013; 4(Suppl 1): S67-S81. doi:10.4103/0976-3147.116472

19. Nguyen JB, Black BR, Leimkuehler MM, Halder V , Nguyen JV , Ahktar N . Intracranial pyogenic abscess: imaging diagnosis utilizing recent advances in computed tomography and magnetic resonance imaging. *Crit Rev Comput Tomogr*. 2004; 45(3): 181-224.

20. Feraco P, Donner D, Gagliardo C, Leonardi I, Piccinini S, Del Poggio A, et al. Cerebral abscesses imaging: A practical approach. *J PopulTherClinPharmacol*. 2020 Jul 11; 27 (3): e11-e24.

21. Yoge R, Bar-Meir M. Management of brain abscesses in children. *Pediatr Infect Dis J*. 2004 Feb; 23(2): 157-159.

22. Kocherry XG, Hegde T, Sastry KV, Mohanty A. Efficacy of stereotactic aspiration in deep-seated and eloquent-region intracranial pyogenic abscesses. *Neurosurg Focus*. 2008; 24(6):E13.

23. Honda H, Warren DK. Central nervous system infections: meningitis and brain abscess. *Infect Dis Clin North Am*. 2009 Sep; 23(3): 609-623.

24. Simjian T, Muskens IS, Lamba N, Yunusa I, Wong K, Veronneau R, et al. Dexamethasone Administration and Mortality in Patients with Brain Abscess: A Systematic Review and Meta-

Analysis. *World Neurosurg*. 2018 Jul; 115: 257-263.

25. Ratnaike TE, Das S, Gregson BA, Mendelow AD. A review of brain abscess surgical treatment-78 years: aspiration versus excision. *World Neurosurg*. 2011 Nov; 76(5): 431-436.

26. Young RF. Frazee J. Gas within intracranial abscess cavities: an indication for surgical excision. *Ann Neurol*.1984: 16: 35-39.

27. Britt RH. Enzmann DR. Remington JS. Intracranial infection in cardiac transplant recipients. *Ann Neurol*. 1981: 9:107-119.

28. de Louvois, Gortvai P Hurley R. Bacteriology of abscesses of the central nervous system: a multicentral prospective study. *Br Med J*. 1999; 2: 750-755.

29. Gormley W, Rosenblum M, Cerebral abscess: In: Tindall G Cooper P. Barrow D. The practice of neurosurgery. Philadelphia Lippincott Williams and Wilkins. 1996: 3343-3354.

30. Aydin I.H., Aladage M.A. and Kadioglu H.H., et al. Clinical analysis of cerebral abscesses. *ZentralblNeurochir*. 1988; 49: 210-219.

31. Mathisen G.E. and Johnson J.P. Brain abscess. *Clin Infect Dis*. 1997; 25: 763-781.

32. Kao P.T., Tseng H.K. and Liu C.P., Lee CM . Brain abscess: clinical analysis of 53 cases. *J MicrobiolImmunol Infect*. 2003; 36: 129-136.

33. Yang S.Y. Brain abscess: a review of 400 cases. *J Neurosurg*. 1981; 55: 794-799.

34. Morgan H. Wood MW. Murphey F. Experience with 88 consecutive cases of brain abscess. *J Neurosurg*. 1973: 38: 698-704.

35. Levy RM. Bredesen DE. Rosenblum ML. Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature. *J Neurosurg*. 1985: 62:475-495.

36. Nielsen H. Gyldensted C. Harmsen A. Cerebral abscess, Aetiology and pathogenesis, symptoms, diagnosis and treatment, A review of 200 cases from 1935-1976. *ActaNeurolScand*. 1982: 65:609-622.

37. Mamilam T.J. Rosenblum ML. Trends in the management of bacterial brain abscesses: a review of 102 cases over 17 years. Neurosurgery 1988: 23:451-458.

38. Samson DS. Clark K. A current review of brain abscess. *AM J Med*. 1973: 54:201-210.
39. Britt RH, Enzmann DR, Remington JS. Intracranial infection in cardiac transplant recipients. *Ann Neurol*. 1981; 9:107-119.
40. Beller AJ, Sahar A, Praiss I. Brain abscess: review of 89 cases over a period of 30 years. *J Neurol Psychiatry*. 1973; 36:757-767.
41. Kagawa M., Takeshita M. and Yato S. Brain abscess in congenital cyanotic heart disease. *J Neurosurg*. 1983; 58: 913-917.
42. Barsoum A.H., Lewis H.C. and Cannillo K.L. Non operative treatment of multiple brain abscesses. *Surg Neurol*. 1981; 16: 283-287.
43. Kratimenos G. and Crockard H.A. Multiple brain abscess: a review of fourteen cases. *Br J Neurosurg*. 1991; 5: 153-161.
44. Mamelak A.N., Mampalam T.J and Obana W.G., Rosenblum M.L. Improved management of multiple brain abscesses: a combined surgical and medical approach. *Neurosurgery*. 1995; 36: 76-85.
45. Dyste G.N., Hitchon P.W. and Menezes A.H., VanGilder J.C., Greene G.M. Stereotaxic surgery in the treatment of multiple brain abscesses. *J Neurosurg*. 1988; 69: 153-188.
46. Bagdatoglu H., Iidan F. and Cetinalp E., Doganay M., Boyar B., Uzuneyupoglu Z., et al. The clinical presentation of intracranial abscesses. A study of seventy-eight cases. *J Neurosurg Sci*. 1992; 36: 139-143.
47. Miller E.S., Dias P.S. and Uttley D. CT scanning in the management of intracranial abscess: a review of 100 cases. *Br J Neurosurg*. 1988; 2: 439-446.
48. Carey ME, Chou SN, French LA. Experience with brain abscesses. *J Neurosurg*. 1972: 36:1-9.
49. Seydoux C. and Francioli P. Bacterial brain abscesses: factors influencing mortality and sequelae. *Clin Infect Dis*. 1992; 5: 394-401.